SCBio CEO steps down to launch Vikor-affiliated startup.

CEO Sam Konduros calls his time with SCBio a "four-year honeymoon," but new opportunities for the life science lynchpin lie on the horizon.

Starting in May, Konduros will pass the torch to COO and Vice President Erin Ford, who will take on the role of interim CEO, as he spearheads a rising health innovation venture with executives of Charleston-based Vikor Scientific.

He said it is another opportunity to exercise his penchant for building companies and initiatives from the ground up, "which seems to be my calling card to some extent, because this will be a new company in their portfolio company."

Konduros said he can't share specifics about the startup until early May, but he told GSA Business Report that he will step in as the company's CEO while serving on Vikor Scientific's board of directors.

The startup will be geared toward "delivering a novel blueprint to the health care marketplace, powered by AI and blockchain technologies and focuses on science-based personalized medicine strategies to solve some of the nation's most pressing health care challenges," according to a news release today.

The Vikor portfolio company will not be affiliated with Vikor's and Quantgene Inc.'s new cancer-preventative treatment, Serenity, and corresponding innovation division Korlife, he said, but does follow Vikor's recent burst in "explosive growth" as the company has spread its impact from Charleston to Philadelphia over the past three years.

"They recently acquired a pathology lab in Tampa, and this will be the next significant diversification for the company," he said, adding that he aims to be "able to help in any way that I can with the overall strategic direction of the company, but clearly, I will be highly focused in a CEO role, building and leading a new team of executives and developing facilities in relation to the new company we will be talking about maybe in less than a month."

Konduros is working closely with SCBio's board leadership on a transition strategy as they search for Konduros' successor.

"Sam Konduros has been a force for economic development, for life sciences and for the long-term prosperity of South Carolina," SCBio Board of Directors Chair Lou Kennedy, also the CEO of Nephron Pharmaceuticals, said in the news release. "It has been an honor to work with him. He has made a remarkable impact on this organization, and he leaves it better than he found it, as one of the most influential associations in the state. We thank Sam for...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT